Galmed Pharmaceuticals

Company Overview

Snapshot

Founded in January 2000, Galmed Pharmaceuticals operates with 1–10 employees. The company has raised a total of $150.3M across 5 funding rounds. In May 2026, Galmed Pharmaceuticals partnered with Tissue Dynamics to develop a human-centered chronic cardiac fibrosis platform to advance Aramchol-based therapeutics.

Business overview

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases. Its core product, Aramchol, a drug candidate for the treatment of NASH and fibrosis, is currently in a Phase 3 registrational study. The company also collaborates with the Hebrew University on Amilo-5MER, a 5 amino acid synthetic peptide, and recently initiated a first-in-human study. Galmed Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Drugs Discovery & Development industries.

Strategic signal

In June 2026, Galmed Pharmaceuticals announced its intent to acquire Colospan, aiming to create a GI-focused platform targeting a $6 billion market. This strategic acquisition signals Galmed's ambition to expand its therapeutic areas and market reach beyond its current focus, indicating a significant growth trajectory and potential for increased market share in the gastrointestinal disease space.

Company Intelligence Q&A

What was a significant recent collaboration for Galmed Pharmaceuticals?

In May 2026, Galmed Pharmaceuticals partnered with Tissue Dynamics to develop a human-centered chronic cardiac fibrosis platform to advance Aramchol-based therapeutics.

What was a key strategic move by Galmed Pharmaceuticals in June 2026?

In June 2026, Galmed Pharmaceuticals announced its acquisition of Colospan, with the goal of establishing a GI-focused platform to target a $6 billion market.

What were the results of the first-in-man pharmacokinetics study of Aramchol Meglumine?

In May 2026, Galmed Pharmaceuticals announced that the first-in-man pharmacokinetics study of oral formulation of Aramchol Meglumine (AM) showed that 400mg AM increases bioavailability by approximately 500% compared to Aramchol Free Acid (AA) 300mg.

What was a key finding regarding Aramchol's potential in oncology in November 2025?

In November 2025, Galmed Pharmaceuticals announced top-line results in oncology MoA studies, indicating that a 3-drug combination of Aramchol, Stivarga, and Metformin significantly enhanced GI tumor cell killing in vivo and in vitro.

What was a significant financial reporting event for Galmed Pharmaceuticals in March 2026?

In March 2026, Galmed Pharmaceuticals Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025.